Opportunities

The IMA seeks to support meritorious projects targeted at using patient-derived organoids to develop critical assays for informing the selection of innovative drug candidates. This RFP specifically supports organoids exclusively comprised of epithelial cells, as opposed to those that also contain mesenchymal stroma and/or immune elements. The use of epithelial organoids from any healthy or diseased tissue is allowable.

The Stanford Innovative Medicines Accelerator (IMA) is dedicated to accelerating the prototyping of innovative translational gene and cell therapies that target unmet clinical needs. Basic research is outside the scope of the current RFP solicitation. While new technology development per se is also outside the scope of the RFP, leveraging an emerging technology to therapeutically address a specific clinical need is encouraged.

The IMA seeks to support human subjects research that will advance the clinical development of new—or extend the use of existing—medicines, vaccines and diagnostics. This could be a proof-of-concept trial for new medication, a new indication for an existing proprietary or generic drug, or a companion diagnostic tool.

The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals for projects that address two major challenges in drug development: identification of drug candidates and optimization towards clinical leads. Through this request for proposals, the IMA is soliciting Letters of Intent (LOI) for projects that fall under the protein therapeutics discovery module.

The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in small-molecule drug discovery: identifying medicinal leads and optimizing medicinal leads into drug prototypes. 

The Innovative Medicines Accelerator (IMA), partnering with the Center for Definitive and Curative Medicine (CDCM) and the Center for Cancer Cell Therapy (CCT), seeks to accelerate the prototyping of innovative early-stage translational stem cell and gene therapies that address unmet clinical needs. 

The IMA is accepting proposals to address unmet medical needs through human subjects research. Through this solicitation, the IMA seeks to support research projects aimed at testing hypotheses in human subjects that, if validated, have the potential to pave the road to new medicines, vaccines and diagnostics or to enhance clinical use of existing ones.

Stanford University’s Innovative Medicines Accelerator (IMA) is accepting proposals that address two major challenges in drug development: identifying drug leads and optimizing drug prototypes. 

Stanford University’s Innovative Medicines Accelerator (IMA) is accepting proposals for projects that leverage a recent technological advance in human organ modeling to address the IMA’s goals of accelerating the prototyping of innovative medicines and vaccines and enabling hypothesis-driven studies on human subjects. S